Gemtuzumab Ozogamicin

In this video, Naval Daver, MD, discusses a presentation on updates in immune and cellular therapy in acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Researchers reported early evidence of anti-leukemic effect in a phase 1b study of combination gemtuzumab ozogamicin and venetoclax in relapsed or refractory acute myeloid leukemia patients in a presentation at the ASCO20 Virtual Scientific Program.

In this video, Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses the state of the pipeline for acute myeloid leukemia, including promising new targeted agents and bispecific antibodies.